{"id":3992,"date":"2023-09-27T10:22:48","date_gmt":"2023-09-27T10:22:48","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/"},"modified":"2026-02-17T13:26:10","modified_gmt":"2026-02-17T13:26:10","slug":"mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov","status":"publish","type":"poster","link":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/","title":{"rendered":"Mitochondrial dysfunction, an in vitro model of neurodegenerative disorders: a focus on multiple endpoints, humanisation, and drug discovery platforms to enable new therapeutic discovery"},"content":{"rendered":"<p>Mitochondrial dysfunction is a common feature in several neurodegenerative disorders (NDs), and there is considerable R&amp;D effort to develop treatments aimed at improving the function of these organelles. Therefore, validated and reproducible measures of mitochondrial (dys)function are crucial to reliably inform basic disease understanding and R&amp;D projects.<\/p>\n<p>We analysed various aspects of mitochondrial function in an <em>in vitro<\/em> model of mitochondrial dysfunction. To induce this dysfunction, we used SHSY5Y cells exposed to Rotenone, a mitochondrial complex I inhibitor commonly used to induce Parkinson&rsquo;s disease. Our assessments included mitochondrial membrane potential (MMP), oxidative stress, Ca2+ homeostasis, oxygen consumption rate (OCR), ATP, ADP, Pyruvate, Lactate, NAD+, and NADH levels. This knowledge is used to study mitochondrial function in fibroblasts from PD patients and human iPSC-derived neurons with PD mutations, using a miniaturized 384-well plate format. This approach humanizes, miniaturizes, and automates assays, enhancing the translational value and speed of <a href=\"https:\/\/www.sygnaturediscovery.com\/drug-discovery\/in-vivo-pharmacology-and-in-vivo-testing\/cns-disorder-models\/\">CNS drug discovery<\/a> for novel treatments.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In our study, we explored various aspects of mitochondrial function using an in vitro model of dysfunction, offering valuable insights into the development of treatments for neurodegenerative disorders. We assessed mitochondrial membrane potential, oxidative stress, Ca2+ homeostasis, oxygen consumption rate, and various metabolic factors, enabling us to enhance the speed and translational value of CNS drug discovery.<\/p>\n","protected":false},"featured_media":2655,"template":"","category":[681,709,753,688],"class_list":["post-3992","poster","type-poster","status-publish","has-post-thumbnail","hentry","category-bioscience","category-cell-based-assays","category-neuroscience","category-therapeutic-areas"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mitochondrial Dysfunction: In vitro Neurodegeneration Model<\/title>\n<meta name=\"description\" content=\"Rotenone-treated SH-SY5Y cells, PD patient fibroblasts and iPSC-derived neurons profiled for membrane potential, OCR and ATP in 384-well format. View more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mitochondrial Dysfunction: In vitro Neurodegeneration Model\" \/>\n<meta property=\"og:description\" content=\"Rotenone-treated SH-SY5Y cells, PD patient fibroblasts and iPSC-derived neurons profiled for membrane potential, OCR and ATP in 384-well format. View more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-17T13:26:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/SFN_2022-TR-NEW-BACKGROUND-e1744810701950.png\" \/>\n\t<meta property=\"og:image:width\" content=\"888\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\\\/\",\"name\":\"Mitochondrial Dysfunction: In vitro Neurodegeneration Model\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/SFN_2022-TR-NEW-BACKGROUND-e1744810701950.png\",\"datePublished\":\"2023-09-27T10:22:48+00:00\",\"dateModified\":\"2026-02-17T13:26:10+00:00\",\"description\":\"Rotenone-treated SH-SY5Y cells, PD patient fibroblasts and iPSC-derived neurons profiled for membrane potential, OCR and ATP in 384-well format. View more.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/SFN_2022-TR-NEW-BACKGROUND-e1744810701950.png\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/SFN_2022-TR-NEW-BACKGROUND-e1744810701950.png\",\"width\":888,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mitochondrial dysfunction, an in vitro model of neurodegenerative disorders: a focus on multiple endpoints, humanisation, and drug discovery platforms to enable new therapeutic discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature Discovery\",\"alternateName\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.youtube.com\\\/@sygnature.discovery\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sygnature-discovery\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mitochondrial Dysfunction: In vitro Neurodegeneration Model","description":"Rotenone-treated SH-SY5Y cells, PD patient fibroblasts and iPSC-derived neurons profiled for membrane potential, OCR and ATP in 384-well format. View more.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/","og_locale":"fr_CA","og_type":"article","og_title":"Mitochondrial Dysfunction: In vitro Neurodegeneration Model","og_description":"Rotenone-treated SH-SY5Y cells, PD patient fibroblasts and iPSC-derived neurons profiled for membrane potential, OCR and ATP in 384-well format. View more.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/","og_site_name":"Sygnature","article_modified_time":"2026-02-17T13:26:10+00:00","og_image":[{"width":888,"height":628,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/SFN_2022-TR-NEW-BACKGROUND-e1744810701950.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/","name":"Mitochondrial Dysfunction: In vitro Neurodegeneration Model","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/SFN_2022-TR-NEW-BACKGROUND-e1744810701950.png","datePublished":"2023-09-27T10:22:48+00:00","dateModified":"2026-02-17T13:26:10+00:00","description":"Rotenone-treated SH-SY5Y cells, PD patient fibroblasts and iPSC-derived neurons profiled for membrane potential, OCR and ATP in 384-well format. View more.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/SFN_2022-TR-NEW-BACKGROUND-e1744810701950.png","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/SFN_2022-TR-NEW-BACKGROUND-e1744810701950.png","width":888,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/mitochondrial-dysfunction-an-in-vitro-model-of-neurodegenerative-disorders-a-focus-on-multiple-endpoints-humanisation-and-drug-discovery-platforms-to-enable-new-therapeutic-discov\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Mitochondrial dysfunction, an in vitro model of neurodegenerative disorders: a focus on multiple endpoints, humanisation, and drug discovery platforms to enable new therapeutic discovery"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","alternateName":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.youtube.com\/@sygnature.discovery","https:\/\/www.linkedin.com\/company\/sygnature-discovery\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/poster"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3992\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/2655"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=3992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=3992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}